AKRO - Akero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trial

Akero Therapeutics ([[AKRO]] -1.4%) announces that its non-alcoholic steatohepatitis ((NASH)) treatment efruxifermin ((EFX)) met its primary endpoint of reducing liver fat in a mid-stage trial.The company announced that the full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in the journal Nature Medicine.The study was a randomized, controlled trial across 27 U.S. sites that enrolled 80 biopsy-confirmed, pre-cirrhotic NASH patients (F1 to F3 fibrosis stage) who received either placebo or EFX for 16 weeks as a weekly subcutaneous injection in one of three doses: 28 mg, 50 mg, or 70 mg.The study met its primary endpoint of absolute change from baseline in hepatic fat fraction measured at week 12, with 48 percent of EFX patients across dose groups achieving normal levels of liver fat (defined as less than 5 percent liver fat), compared with 5 percent of placebo patients.Reductions in liver fat

For further details see:

Akero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trial